Immune Cell Modulation of Patient-Matched Organoid Drug Response in Precision Cancer Medicine Platform
Cells · 2026
DOI: 10.3390/cells15030259 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Silje Kjølle und 14 weiteren Autor:innen. Beteiligte Einrichtung: Biotech Research and Innovation Centre (BRIC), University of Copenhagen (UCPH), 2200 Copenhagen, Denmark. Hauptthemen laut MEDLINE: Precision Medicine, Organoids, Neoplasms, Antineoplastic Agents. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Danish Cancer Society, Innovation Fund Denmark.
Abstract (Originalsprache)
Cancer is one of the leading causes of death worldwide, and the majority of cancer-related deaths are caused by cancer that has spread to other organs. Precision cancer medicine (PCM) holds potential to improve outcomes and relies on molecularly matched therapies based on cancer cell specific molecular alterations. The tumor immune microenvironment plays an important role beyond response to therapy; however, this is generally not considered in current PCM platforms. We established patient-matched organoids and immune cell cultures for drug testing in mono- and co-culture treatment setups using three distinct treatment strategies (pretreatment, co-culture treatment, and T-cell bispecific antibody testing). Response to treatment and impact of immune cells were evaluated by tumor cell viability assays and flow cytometry analysis. Phenotypic analysis showed high heterogeneity of tumor-infiltrating lymphocytes (TILs) across the patients and low immune cell portions of organoids, emphasizing the need for a patient-matched co-culture PCM approach. Our in-depth study of three patients revealed an effect of the patients’ immune cells on drug response and T-cell bispecific antibody treatment in vitro. Here, we illustrate a state-of-the-art co-culture PCM pipeline for patient-matched organoids and immune cells replicating patient response to treatment at the time of biopsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biotech Research and Innovation Centre (BRIC), University of Copenhagen (UCPH), 2200 Copenhagen, Denmark.
- National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, 2730 Herlev, Denmark.
- The Phase I Unit, Department of Oncology, Rigshospitalet, 2100 Copenhagen, Denmark.
- Center for Genomic Medicine, Rigshospitalet, 2100 Copenhagen, Denmark.
ORCID-Profile: Silje Kjølle, Darío Beceiro Ramos, Kamilla Westarp Zornhagen, Perrine Verdys, Martin Højgaard, Ulrik Lassen, Inge Marie Svane, Kristoffer Staal Rohrberg, Marco Donia, Janine T Erler
Förderung
- Danish Cancer Society
- Innovation Fund Denmark
Zitieren
APA
Kjølle, S., Presti, M., Roque, J. P., Bisgaard, L. H., Beceiro Ramos, D., Zornhagen, K. W., Yde, C. W., Schmidt, A. Y., Verdys, P., Højgaard, M., Lassen, U., Svane, I. M., Rohrberg, K. S., Donia, M., & Erler, J. T. (2026). Immune Cell Modulation of Patient-Matched Organoid Drug Response in Precision Cancer Medicine Platform. Cells. https://doi.org/10.3390/cells15030259
Vancouver
Kjølle S, Presti M, Roque JP, Bisgaard LH, Beceiro Ramos D, Zornhagen KW, et al. Immune Cell Modulation of Patient-Matched Organoid Drug Response in Precision Cancer Medicine Platform. Cells. 2026. doi:10.3390/cells15030259
BibTeX
@article{Kjlle2026,
author = {Kjølle, Silje and Presti, Mario and Roque, Jéssica de Pina and Bisgaard, Lina Hua and Beceiro Ramos, Darío and Zornhagen, Kamilla Westarp and Yde, Christina Westmose and Schmidt, Ane Yde and Verdys, Perrine and Højgaard, Martin and Lassen, Ulrik and Svane, Inge Marie and Rohrberg, Kristoffer Staal and Donia, Marco and Erler, Janine T},
title = {Immune Cell Modulation of Patient-Matched Organoid Drug Response in Precision Cancer Medicine Platform},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15030259}
}
EUVIMED